Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 3/20 | 0.45 |
| ▸ | XPO1 | O14980 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11298985 | 0.82 | PTPN11 (0.63) | PTPN11MEN1KMT2AHPGDPRKCI | |
| SCHEMBL4559593 | 0.81 | PTPN11 (0.56) | PTPN11MEN1KMT2APRKCIALDH1A1 | |
| SCHEMBL16465324 | 0.78 | PRKCI (0.52) | PTPN11MEN1KMT2APRKCIALDH1A1 | |
| SCHEMBL4559143 | 0.74 | KMT2A (0.51) | PTPN11MEN1KMT2AHPGDPRKCI | |
| SCHEMBL560665 | 0.71 | ATR (0.65) | ATRPRKDC | |
| SCHEMBL4560198 | 0.70 | KDM4E (0.65) | PRKCIALDH1A1ATRADORA3 | |
| SCHEMBL4559637 | 0.70 | PTPN11 (0.45) | PTPN11MEN1KMT2APRKCIALDH1A1 | |
| SCHEMBL11646761 | 0.70 | GCK (0.50) | MEN1KMT2AHPGDPRKCIALDH1A1 | |
| SCHEMBL11689181 | 0.70 | GCK (0.62) | MEN1KMT2AHPGDPRKCIALDH1A1 | |
| SCHEMBL6582057 | 0.70 | PTPN11 (0.59) | PTPN11MEN1KMT2AHPGDPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065964-B2 | Pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors | Ziarco Pharma Ltd. (GB) | 2018-09-04 | — | — | US | disclosed |
| US-20170145019-A1 | 2-(2-AMINOCYCLOHEXYL)AMINO-PYRIMIDINE-5-CARBOXAMIDES AS SPLEEN TYROSINE KINASE(SYK) INHIBITORS | PFIZER LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9533989-B2 | Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors | Ziarco Pharma Ltd. (GB) | 2017-01-03 | — | — | US | disclosed |
| US-20150232470-A1 | 2-(-Aminocyclohexyl)Amino-Pyrimidine-5-Carboxamides as Spleen Tyrosine Kinasei(SYK) Inhibitors | PFIZER LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| EP-2897950-A1 | 2-(2-AMINOCYCLOHEXYL)AMINO-PYRIMIDINE-5-CARBOXAMIDES AS SPLEEN TYROSINE KINASEI(SYK) INHIBITORS | Ziarco Pharma Ltd (GB) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014045029-A1 | 2-(2-AMINOCYCLOHEXYL)AMINO-PYRIMIDINE-5-CARBOXAMIDES AS SPLEEN TYROSINE KINASEI(SYK) INHIBITORS | ZIARCO PHARMA LTD (GB) | 2014-03-27 | — | — | WO | disclosed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145019-A1 | 2-(2-AMINOCYCLOHEXYL)AMINO-PYRIMIDINE-5-CARBOXAMIDES AS SPLEEN TYROSINE KINASE(SYK) INHIBITORS | SYK, BTK, LCK | PTPN11 309/4885MEN1 4865/4885KMT2A 1785/4885 |
| US-10065964-B2 | Pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors | SYK, LCK, BTK | PTPN11 251/4885MEN1 4820/4885KMT2A 2371/4885 |
| US-20150232470-A1 | 2-(-Aminocyclohexyl)Amino-Pyrimidine-5-Carboxamides as Spleen Tyrosine Kinasei(SYK) Inhibitors | SYK, BTK, LCK | PTPN11 265/4885MEN1 4843/4885KMT2A 1763/4885 |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | PTPN11 1278/4885MEN1 134/4885KMT2A 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.